Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 2/2013

01-04-2013 | Head and Neck Cancers (EY Hanna, Section Editor)

Efficacy of Neck Dissection in the Management of Isolated Nodal Recurrence after Head and Neck Cancer Treatment

Author: Jimmy Yu–wai Chan

Published in: Current Oncology Reports | Issue 2/2013

Login to get access

Abstract

The status of the regional cervical lymphatics is one of the most significant prognostic indicators in head and neck cancers. The traditional treatment for cancers with cervical nodal metastasis has been surgical. With the global trend towards organ-preserving therapy, chemoradiation has gained increasing popularity over primary surgical therapies for cancers in the head and neck region. The subsequent management of the neck for those with residual or recurrent nodal metastasis, however, has become one of the most debated topics in the field of head and neck oncology. This review addressed several important controversies, including the optimal assessment of the nodal response to chemoradiation, the potential role and the oncological results of planned and salvage neck dissection after chemoradiation, as well as the type and extent of neck dissection required in order to achieve the optimal balance between tumour control and surgical morbidities. Further clinical trials and on-going research will help us to define the best therapeutic option in such circumstances.
Literature
1.
Morgan JE, Breau RL, Suen JY, et al. Surgical wound complications after intensive chemoradiotherapy for advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2007;133:10–4.PubMedCrossRef
2.
Grabenbauer GG, Rodel C, Ernst-Stecken A, et al. Neck dissection following radiochemotherapy of advanced head and neck cancer—For selected cases only? Radiother Oncol. 2003;66:57–63.PubMedCrossRef
3.
Simon C, Geopfert H, Rosenthal DI, et al. Presence of malignancy tumour cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival. Eur Arch Otorhinolaryngol. 2006;263:313–8.PubMedCrossRef
4.
Robbins KT, Doweck I, Samant S, et al. Effectiveness of superselective and selective neck dissection for advanced nodal metastases after chemoradiation. Arch Otolaryngol Head Neck Surg. 2005;131:965–9.PubMedCrossRef
5.
Brizel DM, Prosnitz RG, Hunter S, et al. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;58:1418–23.PubMedCrossRef
6.
Lavertu P, Adelstein DJ, Saxton JP, et al. Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer. Head Neck. 1997;19:559–66.PubMedCrossRef
7.
Clayman GL, Johnson CJ, Morrison W, et al. The role of neck dissection after chemoradiotherapy for oropharyngeal cancer with advanced nodal disease. Arch Otolaryngol Head Neck Surg. 2001;127:135–9.PubMed
8.
Corry J, Peters L, Fisher R, et al. N2–N3 neck nodal control without planned neck dissection for clinical / radiologic complete responders – results of Trans Tasman Radiation Oncology Group Study 98.02. Head Neck. 2008;30:737–42.PubMedCrossRef
9.
Liauw SL, Mancuso AA, Amdur RJ, et al. Post-radiotherapy neck dissection for lymph node-positive head and neck cancer: the use of computed tomography to manage the neck. J Clin Oncol. 2006;24:1421–7.PubMedCrossRef
10.
Adelstein DJ, Saxton JP, Rybicki LA, et al. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol. 2006;24:1064–71.PubMedCrossRef
11.
Rogers JW, Greven KM, McGuirt WF, et al. Can post-RT neck dissection be omitted for patients with head-and-neck cancer who have a negative PET scan after definitive radiation therapy? Int J Radiat Oncol Biol Phys. 2004;58:694–7.PubMedCrossRef
12.
Gourin CG, Williams HT, Seabolt WN, et al. Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer. Laryngoscope. 2006;116:705–10.PubMedCrossRef
13.
Greven KM, Williams DW, Keyes Jr JW, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer. 1994;74:1355–9.PubMedCrossRef
14.
Yao M, Luo P, Hoffman HT, et al. Pathology and FDG PET correlation of residual lymph nodes in head and neck cancer after radiation treatment. Am J Clin Oncol. 2007;30:264–70.PubMedCrossRef
15.
Lavertu P, Bonafede JP, Adelstein DJ, et al. Comparison of surgical complications after organ-preservation therapy in patients with stage III or IV squamous cell head and neck cancer. Arch Otolaryngol Head Neck Surg. 1995;121:162–5.CrossRef
16.
Bernier J, Bataini JP. Regional outcome in oropharyngeal and pharyngolaryngeal cancer treated with high dose per fraction radiotherapy. Analysis of neck disease response in 1646 cases. Radiother Oncol. 1986;6:87–103.PubMedCrossRef
17.
Temam S, Pape E, Janot F, et al. Salvage surgery after failure of very accelerated radiotherapy in advanced head-and-neck squamous cell carcinoma with clinically positive neck nodes. Head Neck. 1999;21:591–4.CrossRef
18.
Liauw SL, Amdur RJ, Morris CG, et al. Isolated neck recurrence after definitive radiotherapy for node-positive head and neck cancer: salvage in the dissected or undissected neck. Head Neck. 2007;29:715–9.PubMedCrossRef
19.
Mabanta SR, Mendenhall WM, Stringer SP, Cassisi NJ. Salvage treatment for neck recurrence after irradiation alone for head and neck squamous cell carcinoma with clinically positive neck nodes. Head Neck. 1999;21(7):591–4.PubMedCrossRef
20.
• van der Putten L, van den Broek GB, de Bree R, et al. Effectiveness of salvage selective and modified radical neck dissection for regional pathologic lymphadenopathy after chemoradiation. Head Neck. 2009;31(5):593–603. This study demonstrated poor results of salvage neck dissection after chemoradiation.PubMedCrossRef
21.
Ferlito A, Corry J, Silver CE, Shaha AR, Thomas Robbins K, Rinaldo A. Planned neck dissection for patients with complete response to chemoradiotherapy: a concept approaching obsolescence. Head Neck. 2010;32(2):253–61.PubMed
22.
Soltys SG, Choi CY, Fee WE, Pinto HA, Le QT. A planned neck dissection is not necessary in all patients with N2-3 head-and-neck cancer after sequential chemoradiotherapy. Int J Radiat Oncol Bio Phys. 2011;83(3):994–9.
23.
Thariat J, Ang KK, Allen PK, et al. Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Bio.
24.
Stenson KM, Haraf DJ, Pelzer H, et al. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg. 2000;126:950–6.PubMed
25.
Robbins KT, Wong FS, Kumar P, et al. Efficacy of targeted chemoradiation and planned selective neck dissection to control bulky nodal disease in advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 1999;125(6):670–5.PubMed
26.
Cannady SB, Lee WT, Scharpf J, et al. Extent of neck dissection required after concurrent chemoradiation for stage IV head and neck squamous cell carcinoma. Head Neck. 2010;32(3):348–56.PubMed
27.
Mukhija V, Gupta S, Jacobson AS, et al. Selective neck dissection following adjuvant therapy for advanced head and neck cancer. Head Neck. 2009;31:183–8.PubMedCrossRef
28.
Nouraei SAR, Upile T, Al-Yaghchi C, et al. Role of planned postchemoradiotherapy selective neck dissection in the multimodality management of head and neck cancer. Laryngoscope. 2008;118:797–803.PubMedCrossRef
29.
Stenson KM, Huo D, Blair E, et al. Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope. 2006;116:33–6.PubMedCrossRef
30.
Lango MN, Andrews GA, Ahmad S, et al. Postradiotherapy neck dissection for head and neck squamous cell carcinoma: pattern of pathologic residual carcinoma and prognosis. Head Neck. 2009;31:328–37.PubMedCrossRef
31.
Schöder H, Yeung HW, Gonen M, Kraus D, Larson SM. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology. 2004;231:65–72.PubMedCrossRef
32.
•• Dhiwakar M, Robbins KT, Vieira F, Rao K, Malone J. Selective neck dissection as an early salvage intervention for clinically persistent nodal disease following chemoradiation. Head Neck. 2012. doi:10.​1002/​hed. This study demonstrated the safety of selective neck dissection for patients with partial nodal response after chemoradiation.
33.
Robbins KT, Shannon K, Vieira F. Superselective neck dissection after chemoradiation: feasibility based on clinical and pathologic comparisons. Arch Otolaryngol Head Neck Surg. 2007;133(5):486–9.PubMedCrossRef
34.
Goguen LA, Chapuy CI, Sher DJ, et al. Utilizing computed tomography as a road map for designing selective and superselective neck dissection after chemoradiotherapy. Otolaryngol Head Neck Surg. 2010;143(3):367–74.PubMedCrossRef
Metadata
Title
Efficacy of Neck Dissection in the Management of Isolated Nodal Recurrence after Head and Neck Cancer Treatment
Author
Jimmy Yu–wai Chan
Publication date
01-04-2013
Publisher
Current Science Inc.
Published in
Current Oncology Reports / Issue 2/2013
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-013-0294-8

Other articles of this Issue 2/2013

Current Oncology Reports 2/2013 Go to the issue

Evolving Therapies (RM Bukowski, Section Editor)

Enzalutamide, a Second Generation Androgen Receptor Antagonist: Development and Clinical Applications in Prostate Cancer

Head and Neck Cancers (EY Hanna, Section Editor)

Transoral Microsurgery for Treatment of Laryngeal and Pharyngeal Cancers

Evolving Therapies (RM Bukowski, Section Editor)

Tasquinimod: A Novel Angiogenesis Inhibitor–Development in Prostate Cancer

Gastrointestinal Cancers (BG Czito, Section Editor)

Pathological Complete Response After Neoadjuvant Therapy for Rectal Cancer and the Role of Adjuvant Therapy

Evolving Therapies (RM Bukowski, Section Editor)

Cabozantinib as a Novel Therapy for Renal Cell Carcinoma

Gastrointestinal Cancers (BG Czito, Section Editor)

Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer: An Emerging Paradigm?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits